Modeling anti-KLH ELISA data using two-stage and mixed effects models in support of immunotoxicological studies

Journal of Biopharmaceutical Statistics

Volumn 15, Issue 2, 2005, Pages 205-223

  Shkedy, Ziv ^a   Straetemans, Roel ^a   Molenberghs, Geert ^a   Desmidt, Miek ^b   Vinken, Petra ^b   Goeminne, Nick ^b   Coussement, Werner ^b   Van Den Poel, Bob ^b   Bijnens, Luc ^b  

^a HASSELT UNIVERSITY   (Belgium)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

ELISA; EMEA; FDA; Immunotoxicological studies; KLH; Nonlinear mixed effects model; Two stage model; Variance components

Indexed keywords

ANTIBODY; KEYHOLE LIMPET HEMOCYANIN;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; DATA ANALYSIS; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD AND DRUG ADMINISTRATION; IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; MALE; MAXIMUM LIKELIHOOD METHOD; MODEL; NONHUMAN; NONLINEAR MIXED EFFECTS MODEL; NONLINEAR MIXED MODEL; NONLINEAR SYSTEM; PARAMETER; PRIORITY JOURNAL; RAT; RAT STRAIN; REVIEW; STATISTICAL MODEL; T LYMPHOCYTE; TOXICOLOGY; TWO STAGE MODEL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOCYANIN; IMMUNOTOXINS; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; MODELS, IMMUNOLOGICAL; MODELS, STATISTICAL; NONLINEAR DYNAMICS; RATS; RATS, SPRAGUE-DAWLEY; T-LYMPHOCYTES;

EID: 15544374267     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-200048815     Document Type: Review

References (13)

1. Bates, D., Pinheiro, J. (2000). Mixed Effects Models in S and Splus. New York: Springer.
2. Burdon, R. H., Knippenberg, P. H. (1985). Laboratory Techniques in Biochemistry and Molecular Biology. Practice and Theory of Enzyme Immunoassays. Elsevier.
3. Davidian, M., Giltinan, D. M. (1995). Nonlinear Models for Repeated Measurement Data. London: Chapman and Hall.
4. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). (2000). Note for Guidance on Repeated Dose Toxicity (CPMP/SWP/1042/99). Adopted July 2000.
5. Japanese Ministry for Health, Labour and Welfare (MHLW) and Japanese Pharmaceutical Manufacturing Association (JPMA). (2001). Draft Guidance. December 2001.
6. Krys, J. M., Ronlad, R. B., Abbie, C., Jacqueline, G., Shalini, G., Jean, W. L., Steve, J. S., Wendell, C. S., Russell, S. W. (2001). Pharmaceutical Research 18(9):1373-1383.
7. Lindsay, J. K. (2001). Nonlinear Models in Medical Statistics. Oxford: Oxford University Press.
8. Lindstrom, M. J., Bates, D. M. (1990). Nonlinear mixed-effects models for repeated measures data. Biometrics 46:673-687.
9. Royston, P., Altman, D. G. (1994). Regression using fractional polynomials of continuous covariates: Parsimonious parametric modeling. Applied Statistics 43:429-467.
10. Thisted, R.A. (1988). Elements of Statistical Computing. London: Chapman and Hall.
11. US Food and Drug Administration (FDA), Center of Drug Evaluation and Research (CDER). (2002). Immunotoxicology Evaluation of Investigational New Drugs. Adopted October 2002.
12. Vonesh, E. F., Chinchilli, V. M. (1997). Linear and Nonlinear Models for the Analysis of Repeated Measurements. Marcel Dekker.
13. Workshop Report. (2001). Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report.